Health Canada and JTI-Macdonald Corp. meeting: Reduced Risk Products – May 3, 2019

(PDF Version)

Subject

Reduced Risk Products

Date

May 3, 2019

Participants

Health Canada (HC):

• Dana Beaton
  • Director, Office of Policy and Strategic Planning, Tobacco Control Directorate (TCD) (chair)
• Denis Choinière
  • Director, Tobacco Products Regulatory Office, TPRO, TCD
• Manager, Science Division, TCD
• Science Regulatory Officer, Regulatory Division, TCD
• Senior Advisor, Director General’s Office, TCD
• Acting Policy Analyst, TPRO, TCD

JTI-Macdonald Corp. (JTI):

• Dr. Ian Jones
  • Vice President, Reduced Risk Products portfolio
• Caroline Evans
  • Head of Corporate Affairs & Communications

Introduction

A meeting was held at the request of JTI to present:

• Launch of Logic Compact in Canada;
• Science behind JTI’s reduced risk products portfolio;
• Nicotine concentration and nicotine salts.

The Chair opened the meeting by doing round table introductions.

The Chair reminded participants that this meeting is subject to disclosure as per HC’s Openness and Transparency policies. In the interest of transparency, the department stated that it would be making a record of the meeting publicly available. The handling of information and privacy notice was mentioned and acknowledged.

HC also referred to Article 5.3 of the World Health Organization Framework Convention on Tobacco Control, its international obligation to protect tobacco control policies from the vested interests of the tobacco industry. It was acknowledged by the JTI representatives.

Subjects

Device – Logic Compact

JTI provided an overview of its closed-tank system which was launched in Canada in early 2019. Representatives shared a sample of the device along with the company’s e-liquid pods.

JTI representatives presented the voluntary warning message on the packaging. They indicated the company’s desire to increase its portfolio by introducing a vaping product with various nicotine salts concentrations.

JTI representatives presented a deck outlining the prevalence of reduced risk products.

JTI representatives discussed their internal product stewardship and indicated that all individual ingredients undergo a toxicity analysis and risk assessment based on the full ingredient and material disclosures from suppliers, to the single chemical level.

JTI also presented a sales review and noted consumer demand for a product of this type.

Science on e-cigarettes and heated tobacco

JTI highlighted its product portfolio (heated, infused and e-vapor) as well as an emission analysis of smoke and vapor constituents. JTI also presented its findings on nicotine delivery for its products compared to cigarettes and a toxicology assessment for aerosols.

Nicotine concentration and nicotine salts

JTI presented information on the effect of pH on nicotine salts.

Conclusion

The meeting was then concluded.

Documents

• N/A